| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/28/2004 | US20040214215 Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| 10/28/2004 | US20040214195 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| 10/28/2004 | US20040213857 Multi-vitamin and mineral supplement for pregnant women |
| 10/28/2004 | US20040213856 Compositions and methods for treatment of multiple myeloma |
| 10/28/2004 | US20040213851 Disinfecting polymer and articles made therefrom |
| 10/28/2004 | US20040213842 Particularly a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) and/or activity-dependent sodium channel modulators to treat inflammatory bowel disorders, irritable bowel syndrome, slow-transit constipation, non-ulcer dyspepsia, an evacuation an evacuation disorder and functional dysphasia |
| 10/28/2004 | US20040213834 Pharmacological preparation made from a nanopatriculate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 10/28/2004 | US20040213829 Cleansing the body of heavy metals with a primary chelator to move a heavy metal species from the central nervous system into the vascular system; and a secondary chelator to capsure and move the metal into an excretion pathway. |
| 10/28/2004 | US20040213828 Pain relief lollipop compositions and methods |
| 10/28/2004 | US20040213816 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 10/28/2004 | US20040213799 Boosting priming composition with nonreplicating and/or replication impaired strains of poxvirus vectors; forming human immunodeficiency virus inhibitors |
| 10/28/2004 | US20040213796 Immunotherapy for chronic myelocytic leukemia |
| 10/28/2004 | US20040213793 nucleic acid molecule encoding a transmembrane TEM1; Inhibiting neoangiogenesis by administering a molecule with an antibody variable region which specifically binds to an extracellular domain of a Tumor Endothelial Markers (TEMs) protein; polycystic kidney disease; psoriasis |
| 10/28/2004 | US20040213769 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 10/28/2004 | US20040213768 a cell population capable of producing one or more factors, or a cell culture capable of producing one or more factors or conditioned media from a cell culture containing one or more factors |
| 10/28/2004 | US20040213756 Methods and compositions to treat myocardial conditions |
| 10/28/2004 | US20040213744 can be sprayed onto skin to form a breathable film or patch, which remains stable and in place over a period of days;comprises at least one medicament, at least one film former and at least one vehicle |
| 10/28/2004 | US20040211940 Plasminogen Activator Assay Involving an Elastase Inhibitor |
| 10/28/2004 | DE10315702A1 Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis Using Arzneitmittelkombinationen for the treatment of benign prostatic hyperplasia or for the treatment of abacterial prostatitis |
| 10/28/2004 | CA2811272A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2527175A1 Remedies for diseases to be applied to eye |
| 10/28/2004 | CA2523693A1 Bacteriophage for lysis of methylobacterium and compositions and uses thereof |
| 10/28/2004 | CA2522802A1 Biologically active substance-immobilized device |
| 10/28/2004 | CA2522666A1 Combination therapies for chronic obstructive pulmonary disease (copd) |
| 10/28/2004 | CA2522471A1 Methods for the treatment of pain comprising opioid antagonists |
| 10/28/2004 | CA2522462A1 Multi-vitamin and mineral supplement for pregnant women |
| 10/28/2004 | CA2522313A1 Combinations comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or anxiety |
| 10/28/2004 | CA2522311A1 Combinations of paroxetine and 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl-piperidine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]methylamide for treatment of depression and / or anxiety |
| 10/28/2004 | CA2522143A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor |
| 10/28/2004 | CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling |
| 10/28/2004 | CA2522007A1 Methods of preventing or treating respiratory conditions |
| 10/28/2004 | CA2521979A1 Compositions and methods related to production of erythropoietin |
| 10/28/2004 | CA2521925A1 Preparation and purification of synthetic capsaicin |
| 10/28/2004 | CA2521839A1 Augmented cognitive training |
| 10/28/2004 | CA2521649A1 Composition and uses of galectin antagonists |
| 10/28/2004 | CA2521420A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| 10/28/2004 | CA2521379A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2521369A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| 10/28/2004 | CA2518079A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| 10/27/2004 | EP1471143A1 Rheumatoid arthritis disease sensitive gene, its protein, method and kit of judging the onset of rheumatoid arthritis using the same, and method and drugs for treating rheumatoid arthritis |
| 10/27/2004 | EP1471074A2 Methods for improving the conformation of proteins by means of reducing agents |
| 10/27/2004 | EP1471067A1 Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1470817A1 Compositions for preventing human cancer and method of preventing human cancer |
| 10/27/2004 | EP1470815A1 Opiod formulations for treating pain |
| 10/27/2004 | EP1470420A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 10/27/2004 | EP1470249A2 Effectors of innate immunity |
| 10/27/2004 | EP1470240A2 Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2 |
| 10/27/2004 | EP1470239A2 Psoriasin expression by breast epithelial cells |
| 10/27/2004 | EP1470237A2 Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| 10/27/2004 | EP1470115A1 Treatment of male sexual dysfunction |
| 10/27/2004 | EP1470107A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 10/27/2004 | EP1469884A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders |
| 10/27/2004 | EP1469878A2 Fgfr agonists |
| 10/27/2004 | EP1469877A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
| 10/27/2004 | EP1469873A2 Peptidomimetic inhibitors of post-proline cleaving enzymes |
| 10/27/2004 | EP1469870A2 Novel compositions and methods for cancer |
| 10/27/2004 | EP1469862A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 10/27/2004 | EP1469861A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 10/27/2004 | EP1469860A2 Anti-cancer combination and use thereof |
| 10/27/2004 | EP1469858A1 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation |
| 10/27/2004 | EP1469857A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis |
| 10/27/2004 | EP1469855A2 Methods of treating patients suffering from movement disorders |
| 10/27/2004 | EP1469852A2 Nitric oxide donors for treatment of disease and injury |
| 10/27/2004 | EP1469851A1 Melanocortin receptor agonists |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469848A1 Sedative non-benzodiazepine formulations |
| 10/27/2004 | EP1469847A1 Combinations comprising epothilones and anti-metabolites |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1469841A1 Alpha 2 delta ligands to treat tinnitus |
| 10/27/2004 | EP1469839A2 Transmucosal delivery of proton pump inhibitors |
| 10/27/2004 | EP1469835A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 10/27/2004 | EP1469831A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 10/27/2004 | EP1469828A2 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same |
| 10/27/2004 | EP1469827A2 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 10/27/2004 | EP1469810A2 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
| 10/27/2004 | EP1469769A2 Novel compositions and methods for cancer |
| 10/27/2004 | EP1469717A2 Triple transgenic mouse model of alzheimer's disease |
| 10/27/2004 | EP1244457B1 Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases |
| 10/27/2004 | EP1204407B1 Implantable active ingredient depot |
| 10/27/2004 | EP1105391B1 Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation |
| 10/27/2004 | EP1037629B1 Combination of a retinoic acid metabolism blocking agent and a tocophereol |
| 10/27/2004 | EP1027027A4 Therapeutic method |
| 10/27/2004 | EP0910362B1 Oxa acids and related compounds for treating skin conditions |
| 10/27/2004 | CN1541335A EPF receptor assays, compounds and therapeutic compsns. |
| 10/27/2004 | CN1541278A Novel molecular target for neurotoxicity |
| 10/27/2004 | CN1541222A Antibodies to non-functional P 2 Chi 7 receptor diagnosis and treatment of cancers and other conditions |
| 10/27/2004 | CN1541215A HIV inhibiting pyrimidines derivatives |
| 10/27/2004 | CN1541109A Inhibitors of HER3 activity |
| 10/27/2004 | CN1541106A Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 10/27/2004 | CN1541105A Combination therapies using vitamin B12 and interferon for treatment of viral, provliferative and inflammatory diseases |
| 10/27/2004 | CN1541098A Combination therapy for treatment of cancer |
| 10/27/2004 | CN1541094A Treatment of lipodystrophy |
| 10/27/2004 | CN1541093A Novel use of combined 5-HI1A agonists and selective serotonin reuptake inhibitors |
| 10/27/2004 | CN1541092A Method for treating primary insomnia |
| 10/27/2004 | CN1539970A Heterophil neutral leucocyte factor alpha |
| 10/27/2004 | CN1539849A Polypeptides encoded by haman lipase-like gene and compsns, and metods of utilizing same |
| 10/27/2004 | CN1539502A Unique idiocratic innunization method for against cancer |
| 10/27/2004 | CN1172918C Isothizole derivatives useful anticancer agents |
| 10/27/2004 | CN1172719C Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy |